Soleus Capital Management L.P. Increases Stock Position in Takeda Pharmaceutical Company Limited (NYSE:TAK)

Soleus Capital Management L.P. lifted its stake in shares of Takeda Pharmaceutical Company Limited (NYSE:TAK - Free Report) by 136.0% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 1,180,000 shares of the company's stock after buying an additional 680,000 shares during the quarter. Soleus Capital Management L.P.'s holdings in Takeda Pharmaceutical were worth $15,623,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors also recently bought and sold shares of the company. QRG Capital Management Inc. raised its position in shares of Takeda Pharmaceutical by 16.8% in the 4th quarter. QRG Capital Management Inc. now owns 329,644 shares of the company's stock worth $4,364,000 after acquiring an additional 47,490 shares in the last quarter. Russell Investments Group Ltd. boosted its stake in Takeda Pharmaceutical by 48.6% during the fourth quarter. Russell Investments Group Ltd. now owns 45,324 shares of the company's stock worth $600,000 after acquiring an additional 14,831 shares in the last quarter. US Bancorp DE lifted its holdings in shares of Takeda Pharmaceutical by 21.2% during the fourth quarter. US Bancorp DE now owns 124,332 shares of the company's stock valued at $1,646,000 after purchasing an additional 21,744 shares during the last quarter. Blue Trust Inc. boosted its position in shares of Takeda Pharmaceutical by 27.0% in the 4th quarter. Blue Trust Inc. now owns 14,430 shares of the company's stock worth $205,000 after purchasing an additional 3,071 shares in the last quarter. Finally, Dimensional Fund Advisors LP grew its stake in shares of Takeda Pharmaceutical by 60.0% in the 4th quarter. Dimensional Fund Advisors LP now owns 181,929 shares of the company's stock worth $2,409,000 after buying an additional 68,200 shares during the last quarter. 9.17% of the stock is owned by institutional investors.

Takeda Pharmaceutical Stock Up 0.7%

Shares of TAK traded up $0.10 during trading hours on Thursday, hitting $14.42. The company had a trading volume of 1,980,770 shares, compared to its average volume of 1,925,124. The stock has a market capitalization of $45.88 billion, a price-to-earnings ratio of 36.05, a P/E/G ratio of 0.24 and a beta of 0.26. The firm has a fifty day moving average price of $14.72 and a 200-day moving average price of $14.01. Takeda Pharmaceutical Company Limited has a 52-week low of $12.58 and a 52-week high of $15.43. The company has a debt-to-equity ratio of 0.63, a quick ratio of 0.72 and a current ratio of 1.31.

Takeda Pharmaceutical (NYSE:TAK - Get Free Report) last issued its earnings results on Thursday, May 8th. The company reported $0.16 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.24 by ($0.08). The firm had revenue of $7.34 billion during the quarter, compared to analysts' expectations of $8.02 billion. Takeda Pharmaceutical had a return on equity of 9.39% and a net margin of 4.53%. On average, equities research analysts forecast that Takeda Pharmaceutical Company Limited will post 1.64 EPS for the current fiscal year.

Analysts Set New Price Targets

Separately, Morgan Stanley raised Takeda Pharmaceutical from an "equal weight" rating to an "overweight" rating in a report on Wednesday, April 2nd.

Takeda Pharmaceutical Profile

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.